Developer docs
API playgroundTry for free, no card

Search company profiles

OQPBIOM

Full company profile

uuid000z5ot

Namestring
OQPBIOM
Legal namestring
오큐피바이오엠
Websiteurl
oqpbiom.com
Company typeenum
Private
Founded yearstring
-
Descriptiontext

OQPBioM (오큐피바이오엠) is a private, pre-revenue biopharmaceutical company headquartered in Pyongtaek, South Korea, specializing in the development of novel immuno-oncology therapies for cancer. The company is focused on three high-unmet-need oncology indications — ovarian cancer, pancreatic cancer, and metastatic breast cancer — and operates its pipeline through a subsidiary structure holding multiple immunotherapy programs targeting these diseases. Its core competency is monoclonal antibody-based immunotherapy development using immune checkpoint modulation strategies.

The company's lead asset is Oregovomab, a monoclonal antibody immunotherapy for ovarian cancer that demonstrated excellent safety and efficacy in Phase 2 clinical trials and received recognition in leading international gynecological oncology journals. In the second half of 2020, OQPBioM initiated the FDA global Phase 3 clinical trial (FLORA-5) for Oregovomab, positioning the asset as a potential first-in-class immunotherapy for ovarian cancer. The secondary asset, AR20.5, is an immuno-oncology candidate targeting pancreatic cancer and is part of the broader three-indication pipeline. The underlying technology is rooted in proprietary monoclonal antibody design, supported by registered patent/trademark filings on both Oregovomab and AR20.5.

As a development-stage biotech, OQPBioM has not yet generated revenue from product commercialization. Its expected future revenue model is based on drug commercialization, licensing agreements, or strategic partnerships with larger pharmaceutical companies following regulatory approval. In June 2025 the company executed an acquisition of Adbiotech and received an investment from Quest PharmaTech, signaling continued capital deployment and inorganic expansion. The company communicates its pipeline and corporate information through its corporate website (www.oqpbiom.com) and an active IR/PR announcement section, targeting investors, healthcare professionals, and potential partners.

Short descriptiontext

OQPBioM (오큐피바이오엠) is a private South Korean biopharmaceutical company developing monoclonal antibody immuno-oncology therapies for ovarian, pancreatic, and metastatic breast cancer, with lead candidate Oregovomab currently in an FDA global Phase 3 trial (FLORA-5).

Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersPyongtaek, South Korea
HQ citystring
Pyongtaek
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Keyword5 values
immuno-oncology drug development, monoclonal antibody therapy, ovarian cancer immunotherapy, pancreatic cancer treatment, biopharmaceutical R&D
Industry2 codes
PRIMARYHLAIACAA
Oncology Specialty Pharmaceuticals
SECONDARYHLAIACAN
Women’s Health & Reproductive Specialty Pharmaceuticals
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Immuno-oncology biopharmaceuticals
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Development and Commercialization
TypeOne Time License
Description

Pre-revenue biopharmaceutical company developing immunotherapy drugs for cancer treatment. Expected future revenue through drug commercialization, licensing agreements, and/or strategic partnerships with larger pharmaceutical companies upon successful clinical development and regulatory approval.

oqpbiom.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

OQPBioM (오큐피바이오엠) is a pre-revenue, development-stage biopharmaceutical company that researches and develops monoclonal antibody-based immuno-oncology drug candidates for solid tumors. Its pipeline targets ovarian cancer (lead asset Oregovomab, in FDA global Phase 3 FLORA-5 trial initiated in 2H 2020), pancreatic cancer (AR20.5), and metastatic breast cancer, with future revenue expected from drug licensing or commercialization following regulatory approval.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Oregovomab demonstrated excellent safety and efficacy in Phase 2 clinical trials
Product overview1 text field

OQPBIOM is a biotech company specializing in immune-oncology cancer treatment development. The company operates a unified platform focused on cancer immunotherapy, with two named products in their pipeline: Oregovomab for ovarian cancer (Phase 3) and AR20.5 for pancreatic cancer. The company is also developing treatments for metastatic breast cancer. These products are part of a coordinated research portfolio targeting multiple cancer indications using immune-oncology approaches.

Product and service2 records
1Oregovomab (오레고보맙)
CategoryImmuno-oncology drug candidate
Description

Monoclonal antibody immunotherapy drug candidate for ovarian cancer, representing the first immunotherapy developed for this indication. Demonstrated excellent safety and efficacy in Phase 2 clinical trials and is currently progressing through FDA global Phase 3 clinical trial (FLORA-5) initiated in second half of 2020.

2AR20.5
CategoryImmuno-oncology drug candidate
Description

Innovative immune-oncology therapeutic candidate targeting pancreatic cancer, part of the company's pipeline targeting multiple cancer types through cancer antigen-directed immunotherapy.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Biotech focused on immuno-oncology antibody development; comparable as a smaller emerging player in monoclonal antibody cancer therapeutics with similar scale and stage.

TypeDirect peer
Description

Developer of Rubraca (rucaparib), a PARP inhibitor approved for ovarian cancer; directly comparable as a targeted therapy developer competing for ovarian cancer share.

TypeEmerging player
Description

Antibody therapeutics company developing monoclonal antibody oncology candidates using proprietary platforms; comparable as a monoclonal antibody developer in oncology, though broader than OQPBIOM's focus.

TypeBroad incumbent
Description

Major pharma with the leading PARP inhibitor Lynparza in ovarian cancer and broader immuno-oncology franchise; the dominant broad incumbent OQPBIOM would compete against if approved.

TypeDirect peer
Description

Developer of Elahere (mirvetuximab soravtansine), an ADC approved for ovarian cancer; directly comparable as a focused ovarian cancer therapeutic developer with overlapping indication.

6Bristol-Myers Squibb
TypeBroad incumbent
Description

Owns Opdivo (nivolumab), one of the leading checkpoint inhibitor immunotherapies across multiple cancers including ovarian; a broad incumbent OQPBIOM competes against in the immuno-oncology category.

TypeRegional player
Description

Taiwan-based oncology specialty pharma developing and licensing cancer therapeutics across Asia; a comparable regional oncology player with similar development-stage profile and APAC market focus.

TypeDirect peer
Description

Canada-based immuno-oncology company and OncoQuest parent that invested in OQPBIOM in June 2025; shares the same Oregovomab development lineage and ovarian cancer immunotherapy focus.

TypeRegional player
Description

South Korean clinical-stage biotech developing immuno-oncology and other biologics; comparable Korean peer with similar development-stage profile and biotech operating model.

10OncoQuest Pharmaceuticals
TypeDirect peer
Description

Canadian immuno-oncology company that originally developed and held rights to Oregovomab; a direct peer and historical development partner for OQPBIOM's lead asset in ovarian cancer immunotherapy.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

OQPBIOM

Immuno-oncology biopharmaceuticalsoqpbiom.com

OQPBioM (오큐피바이오엠) is a private South Korean biopharmaceutical company developing monoclonal antibody immuno-oncology therapies for ovarian, pancreatic, and metastatic breast cancer, with lead candidate Oregovomab currently in an FDA global Phase 3 trial (FLORA-5).

What OQPBIOM does

OQPBioM (오큐피바이오엠) is a private, pre-revenue biopharmaceutical company headquartered in Pyongtaek, South Korea, specializing in the development of novel immuno-oncology therapies for cancer. The company is focused on three high-unmet-need oncology indications — ovarian cancer, pancreatic cancer, and metastatic breast cancer — and operates its pipeline through a subsidiary structure holding multiple immunotherapy programs targeting these diseases. Its core competency is monoclonal antibody-based immunotherapy development using immune checkpoint modulation strategies.

The company's lead asset is Oregovomab, a monoclonal antibody immunotherapy for ovarian cancer that demonstrated excellent safety and efficacy in Phase 2 clinical trials and received recognition in leading international gynecological oncology journals. In the second half of 2020, OQPBioM initiated the FDA global Phase 3 clinical trial (FLORA-5) for Oregovomab, positioning the asset as a potential first-in-class immunotherapy for ovarian cancer. The secondary asset, AR20.5, is an immuno-oncology candidate targeting pancreatic cancer and is part of the broader three-indication pipeline. The underlying technology is rooted in proprietary monoclonal antibody design, supported by registered patent/trademark filings on both Oregovomab and AR20.5.

As a development-stage biotech, OQPBioM has not yet generated revenue from product commercialization. Its expected future revenue model is based on drug commercialization, licensing agreements, or strategic partnerships with larger pharmaceutical companies following regulatory approval. In June 2025 the company executed an acquisition of Adbiotech and received an investment from Quest PharmaTech, signaling continued capital deployment and inorganic expansion. The company communicates its pipeline and corporate information through its corporate website (www.oqpbiom.com) and an active IR/PR announcement section, targeting investors, healthcare professionals, and potential partners.

OQPBIOM firmographics

Firmographics
Name
OQPBIOM
Legal name
오큐피바이오엠
Website
https://oqpbiom.com
Company type
Private
Operating status
Operating
Short description
OQPBioM (오큐피바이오엠) is a private South Korean biopharmaceutical company developing monoclonal antibody immuno-oncology therapies for ovarian, pancreatic, and metastatic breast cancer, with lead candidate Oregovomab currently in an FDA global Phase 3 trial (FLORA-5).
Ownership category
akta.pro rank

OQPBIOM industry classification

Industry
Product category
Immuno-oncology biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIACAA
Oncology Specialty Pharmaceuticals
SECONDARYHLAIACAN
Women’s Health & Reproductive Specialty Pharmaceuticals

Keywords

  • Immuno-oncology drug development
  • Monoclonal antibody therapy
  • Ovarian cancer immunotherapy
  • Pancreatic cancer treatment
  • Biopharmaceutical R&D

Where OQPBIOM is headquartered

Location

Headquarters

HQ city
Pyongtaek
HQ country
South Korea
HQ region
Asia

Markets served

OQPBIOM business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain

Revenue model

  1. Drug Development and Commercialization: Pre-revenue biopharmaceutical company developing immunotherapy drugs for cancer treatment. Expected future revenue through drug commercialization, licensing agreements, and/or strategic partnerships with larger pharmaceutical companies upon successful clinical development and regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

OQPBIOM product offering

Product offering

Core offering

OQPBioM (오큐피바이오엠) is a pre-revenue, development-stage biopharmaceutical company that researches and develops monoclonal antibody-based immuno-oncology drug candidates for solid tumors. Its pipeline targets ovarian cancer (lead asset Oregovomab, in FDA global Phase 3 FLORA-5 trial initiated in 2H 2020), pancreatic cancer (AR20.5), and metastatic breast cancer, with future revenue expected from drug licensing or commercialization following regulatory approval.

Product overview

OQPBIOM is a biotech company specializing in immune-oncology cancer treatment development. The company operates a unified platform focused on cancer immunotherapy, with two named products in their pipeline: Oregovomab for ovarian cancer (Phase 3) and AR20.5 for pancreatic cancer. The company is also developing treatments for metastatic breast cancer. These products are part of a coordinated research portfolio targeting multiple cancer indications using immune-oncology approaches.

Differentiator

Problem solved

Functional benefit

Products and services

  • Oregovomab (오레고보맙) Monoclonal antibody immunotherapy drug candidate for ovarian cancer, representing the first immunotherapy developed for this indication. Demonstrated excellent safety and efficacy in Phase 2 clinical trials and is currently progressing through FDA global Phase 3 clinical trial (FLORA-5) initiated in second half of 2020.
  • AR20.5 Innovative immune-oncology therapeutic candidate targeting pancreatic cancer, part of the company's pipeline targeting multiple cancer types through cancer antigen-directed immunotherapy.

Quantifiable outcome

  • Oregovomab demonstrated excellent safety and efficacy in Phase 2 clinical trials

Companies that use OQPBIOM

Customer profile

Segments3 records

Ideal customer profiles2 records

OQPBIOM technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

OQPBIOM partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves4 records

Expansion highlights5 records

OQPBIOM competitors and assessment

Company assessment

Emerging players

  • Ottimo Pharma: Biotech focused on immuno-oncology antibody development; comparable as a smaller emerging player in monoclonal antibody cancer therapeutics with similar scale and stage.
  • Genmab: Antibody therapeutics company developing monoclonal antibody oncology candidates using proprietary platforms; comparable as a monoclonal antibody developer in oncology, though broader than OQPBIOM's focus.

Direct peers

  • Clovis Oncology: Developer of Rubraca (rucaparib), a PARP inhibitor approved for ovarian cancer; directly comparable as a targeted therapy developer competing for ovarian cancer share.
  • ImmunoGen: Developer of Elahere (mirvetuximab soravtansine), an ADC approved for ovarian cancer; directly comparable as a focused ovarian cancer therapeutic developer with overlapping indication.
  • Quest PharmaTech: Canada-based immuno-oncology company and OncoQuest parent that invested in OQPBIOM in June 2025; shares the same Oregovomab development lineage and ovarian cancer immunotherapy focus.
  • OncoQuest Pharmaceuticals: Canadian immuno-oncology company that originally developed and held rights to Oregovomab; a direct peer and historical development partner for OQPBIOM's lead asset in ovarian cancer immunotherapy.

Broad incumbents

  • AstraZeneca: Major pharma with the leading PARP inhibitor Lynparza in ovarian cancer and broader immuno-oncology franchise; the dominant broad incumbent OQPBIOM would compete against if approved.
  • Bristol-Myers Squibb: Owns Opdivo (nivolumab), one of the leading checkpoint inhibitor immunotherapies across multiple cancers including ovarian; a broad incumbent OQPBIOM competes against in the immuno-oncology category.

Regional players

  • PharmaEngine: Taiwan-based oncology specialty pharma developing and licensing cancer therapeutics across Asia; a comparable regional oncology player with similar development-stage profile and APAC market focus.
  • Genexine: South Korean clinical-stage biotech developing immuno-oncology and other biologics; comparable Korean peer with similar development-stage profile and biotech operating model.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

OQPBIOM financial estimates

Financial estimate

Revenue estimate

Valuation estimate

OQPBIOM leadership team

Management profile

Number of profiles

OQPBIOM funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

OQPBIOM M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OQPBIOM

What does OQPBIOM do?

OQPBioM (오큐피바이오엠) is a pre-revenue, development-stage biopharmaceutical company that researches and develops monoclonal antibody-based immuno-oncology drug candidates for solid tumors. Its pipeline targets ovarian cancer (lead asset Oregovomab, in FDA global Phase 3 FLORA-5 trial initiated in 2H 2020), pancreatic cancer (AR20.5), and metastatic breast cancer, with future revenue expected from drug licensing or commercialization following regulatory approval.

Is OQPBIOM a public or private company?

OQPBIOM is a private company. It is classified as unknown and is currently operating.

When was OQPBIOM founded?

OQPBIOM was founded in -1.

Where is OQPBIOM based?

OQPBIOM is headquartered in Pyongtaek, South Korea, in the Asia region.

How does OQPBIOM make money?

One revenue line is on record: drug Development and Commercialization.

Who are OQPBIOM's main competitors?

Emerging players on record are Ottimo Pharma and Genmab. Direct peers are Clovis Oncology, ImmunoGen, Quest PharmaTech and OncoQuest Pharmaceuticals. Broad incumbents are AstraZeneca and Bristol-Myers Squibb. Regional players are PharmaEngine and Genexine.

Does OQPBIOM have an API?

No public API is recorded for OQPBIOM.

What industry is OQPBIOM in?

OQPBIOM's product category is Immuno-oncology biopharmaceuticals. Its primary akta.pro industry code is HLAIACAA, Oncology Specialty Pharmaceuticals, with a secondary code of HLAIACAN, Women’s Health & Reproductive Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals